메뉴 건너뛰기




Volumn 74, Issue 5, 2017, Pages 557-566

Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease

(309)  Mattsson, Niklas a,b   Andreasson, Ulf c,d   Zetterberg, Henrik c,d,e   Blennow, Kaj c,d   Weiner, Michael W f   Aisen, Paul g   Toga, Arthur W g   Petersen, Ronald h   Jack, Clifford R h   Jagust, William i   Trojanowki, John Q j   Shaw, Leslie M j   Beckett, Laurel k   Green, Robert C l   Saykin, Andrew J m   Morris, John C n   Khachaturian, Zaven cc   Sorensen, Greg o   Carrillo, Maria p   Kuller, Lew q   more..


Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT LIGHT; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; NEUROFILAMENT PROTEIN L;

EID: 85018870200     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.6117     Document Type: Article
Times cited : (694)

References (27)
  • 1
    • 84946048255 scopus 로고    scopus 로고
    • Revolutionizing Alzheimer's disease and clinical trials through biomarkers
    • Mattsson N, Carrillo MC, Dean RA, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015;1(4):412-419.
    • (2015) Alzheimers Dement (Amst) , vol.1 , Issue.4 , pp. 412-419
    • Mattsson, N.1    Carrillo, M.C.2    Dean, R.A.3
  • 2
    • 77949423619 scopus 로고    scopus 로고
    • Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
    • Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
    • (2010) Nat Rev Neurol , vol.6 , Issue.3 , pp. 131-144
    • Blennow, K.1    Hampel, H.2    Weiner, M.3    Zetterberg, H.4
  • 6
    • 84991224600 scopus 로고    scopus 로고
    • Neurofilament light: A dynamic cross-disease fluid biomarker for neurodegeneration
    • Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016;91(1):1-3.
    • (2016) Neuron , vol.91 , Issue.1 , pp. 1-3
    • Zetterberg, H.1
  • 7
    • 84954224391 scopus 로고    scopus 로고
    • Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression
    • Zetterberg H, Skillback T, Mattsson N, et al; Alzheimer's Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60-67.
    • (2016) JAMA Neurol , vol.73 , Issue.1 , pp. 60-67
    • Zetterberg, H.1    Skillback, T.2    Mattsson, N.3
  • 8
    • 84884497586 scopus 로고    scopus 로고
    • Increased neurofilament light chain blood levels in neurodegenerative neurological diseases
    • Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091.
    • (2013) PLoS One , vol.8 , Issue.9 , pp. e75091
    • Gaiottino, J.1    Norgren, N.2    Dobson, R.3
  • 9
    • 84991281277 scopus 로고    scopus 로고
    • Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases
    • Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(1): 56-66.
    • (2016) Neuron , vol.91 , Issue.1 , pp. 56-66
    • Bacioglu, M.1    Maia, L.F.2    Preische, O.3
  • 10
    • 84977653989 scopus 로고    scopus 로고
    • Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
    • Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-1661.
    • (2016) Clin Chem Lab Med , vol.54 , Issue.10 , pp. 1655-1661
    • Kuhle, J.1    Barro, C.2    Andreasson, U.3
  • 11
    • 84958936131 scopus 로고    scopus 로고
    • Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study
    • Gisslen M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140.
    • (2015) EBioMedicine , vol.3 , pp. 135-140
    • Gisslen, M.1    Price, R.W.2    Andreasson, U.3
  • 12
    • 84977620914 scopus 로고    scopus 로고
    • Plasma neurofilament light chain predicts progression in progressive supranuclear palsy
    • Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216-225.
    • (2016) Ann Clin Transl Neurol , vol.3 , Issue.3 , pp. 216-225
    • Rojas, J.C.1    Karydas, A.2    Bang, J.3
  • 13
    • 74949097405 scopus 로고    scopus 로고
    • Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization
    • Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74(3):201-209.
    • (2010) Neurology , vol.74 , Issue.3 , pp. 201-209
    • Petersen, R.C.1    Aisen, P.S.2    Beckett, L.A.3
  • 14
    • 0021271971 scopus 로고
    • Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
    • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
    • (1984) Neurology , vol.34 , Issue.7 , pp. 939-944
    • McKhann, G.1    Drachman, D.2    Folstein, M.3    Katzman, R.4    Price, D.5    Stadlan, E.M.6
  • 15
    • 84988910596 scopus 로고    scopus 로고
    • Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
    • Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336.
    • (2016) Neurology , vol.87 , Issue.13 , pp. 1329-1336
    • Rohrer, J.D.1    Woollacott, I.O.C.2    Dick, K.M.3
  • 16
    • 65249159879 scopus 로고    scopus 로고
    • Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects
    • Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413.
    • (2009) Ann Neurol , vol.65 , Issue.4 , pp. 403-413
    • Shaw, L.M.1    Vanderstichele, H.2    Knapik-Czajka, M.3
  • 17
    • 41949137974 scopus 로고    scopus 로고
    • The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods
    • Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685-691.
    • (2008) J Magn Reson Imaging , vol.27 , Issue.4 , pp. 685-691
    • Jack, C.R.1    Bernstein, M.A.2    Fox, N.C.3
  • 18
    • 84951033618 scopus 로고    scopus 로고
    • Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings
    • Jack CR Jr, Wiste HJ, Weigand SD, et al. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(pt 12):3747-3759.
    • (2015) Brain , vol.138 , pp. 3747-3759
    • Jack, C.R.1    Wiste, H.J.2    Weigand, S.D.3
  • 19
    • 70349315265 scopus 로고    scopus 로고
    • Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR
    • Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009;21:239-251.
    • (2009) Inf Process Med Imaging , vol.21 , pp. 239-251
    • Schwarz, C.1    Fletcher, E.2    DeCarli, C.3    Carmichael, O.4
  • 20
    • 84862735174 scopus 로고    scopus 로고
    • Amyloid deposition hypometabolism and longitudinal cognitive decline
    • Landau SM, Mintun MA, Joshi AD, et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72 (4):578-586.
    • (2012) Ann Neurol , vol.72 , Issue.4 , pp. 578-586
    • Landau, S.M.1    Mintun, M.A.2    Joshi, A.D.3
  • 21
    • 85002757522 scopus 로고    scopus 로고
    • Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
    • Bergman J, Dring A, Zetterberg H, et al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e271.
    • (2016) Neurol Neuroimmunol Neuroinflamm , vol.3 , Issue.5 , pp. e271
    • Bergman, J.1    Dring, A.2    Zetterberg, H.3
  • 22
    • 84992386036 scopus 로고    scopus 로고
    • Plasma tau in Alzheimer disease
    • Mattsson N, Zetterberg H, Janelidze S, et al; ADNI Investigators. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827-1835.
    • (2016) Neurology , vol.87 , Issue.17 , pp. 1827-1835
    • Mattsson, N.1    Zetterberg, H.2    Janelidze, S.3
  • 23
    • 84855304100 scopus 로고    scopus 로고
    • Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
    • Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69 (1):98-106.
    • (2012) Arch Gen Psychiatry , vol.69 , Issue.1 , pp. 98-106
    • Buchhave, P.1    Minthon, L.2    Zetterberg, H.3    Wallin, A.K.4    Blennow, K.5    Hansson, O.6
  • 24
    • 72049130805 scopus 로고    scopus 로고
    • Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
    • Jack CR Jr, Knopman DS, JagustWJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
    • (2010) Lancet Neurol , vol.9 , Issue.1 , pp. 119-128
    • Jack, C.R.1    Knopman, D.S.2    Jagust, W.J.3
  • 25
    • 84884127276 scopus 로고    scopus 로고
    • Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study
    • Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.
    • (2013) Lancet Neurol , vol.12 , Issue.10 , pp. 957-965
    • Vos, S.J.1    Xiong, C.2    Visser, P.J.3
  • 26
    • 79952808102 scopus 로고    scopus 로고
    • CSF biomarkers in neurodegenerative diseases
    • Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med. 2011;49(3):345-352.
    • (2011) Clin Chem Lab Med , vol.49 , Issue.3 , pp. 345-352
    • Mattsson, N.1
  • 27
    • 84989947774 scopus 로고    scopus 로고
    • Cerebrospinal fluid tau neurogranin and neurofilament light in Alzheimer's disease
    • Mattsson N, Insel PS, Palmqvist S, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med. 2016;8(10):1184-1196.
    • (2016) EMBO Mol Med , vol.8 , Issue.10 , pp. 1184-1196
    • Mattsson, N.1    Insel, P.S.2    Palmqvist, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.